Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative migraine management strategy using both drug classes synergistically.
Key findingNovel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative mi
What the researchers found
Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative migraine management strategy using both drug classes synergistically.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
24-month follow-up across 16 clinic visits evaluating combined CGRP mAb and gepant therapy.
How the study worked
In publication.
Who was studied
Migraine patients on CGRP monoclonal antibodies experiencing wearing-off symptoms
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon.
Clinical neurology and neurosurgery, 258, 109183
Citation
Alsaadi, Taoufik; Adel, Fatema; Alsaffarini, Kareem; El Jadam, Caline; Alkhateri, Athra; Pagdato, Beverly; Suliman, Reem. (2025). Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon.. Clinical neurology and neurosurgery, 258, 109183. https://doi.org/10.1016/j.clineuro.2025.109183